Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for coronary microvascular dysfunction after myocardial infarction
ChiCTR2600135313Phase 4Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Coronary Small Vessel Disease (CMD) and myocardial infarction (MI) comparing Colchicine group with Placebo group (2 arms). Primary endpoint: Target vessel myocardial flow reserve. Started Nov 2024; status: completed.
02
Drugs
colchicine
03
Conditions
Coronary Small Vessel Disease (CMD)myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2600135313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135313.